US Bancorp DE Reduces Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

US Bancorp DE cut its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 31.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 1,719 shares during the period. US Bancorp DE’s holdings in Regeneron Pharmaceuticals were worth $1,164,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in REGN. Parnassus Investments CA boosted its position in Regeneron Pharmaceuticals by 290.6% in the 2nd quarter. Parnassus Investments CA now owns 625,000 shares of the biopharmaceutical company’s stock valued at $195,625,000 after buying an additional 465,000 shares during the period. Prudential Financial Inc. boosted its position in Regeneron Pharmaceuticals by 190.2% in the 2nd quarter. Prudential Financial Inc. now owns 227,517 shares of the biopharmaceutical company’s stock valued at $71,213,000 after buying an additional 149,111 shares during the period. Renaissance Technologies LLC boosted its position in Regeneron Pharmaceuticals by 62.3% in the 2nd quarter. Renaissance Technologies LLC now owns 337,962 shares of the biopharmaceutical company’s stock valued at $105,782,000 after buying an additional 129,700 shares during the period. Nomura Asset Management Co. Ltd. boosted its position in Regeneron Pharmaceuticals by 762.1% in the 1st quarter. Nomura Asset Management Co. Ltd. now owns 145,420 shares of the biopharmaceutical company’s stock valued at $59,712,000 after buying an additional 128,551 shares during the period. Finally, Bessemer Group Inc. boosted its position in Regeneron Pharmaceuticals by 19,776.3% in the 2nd quarter. Bessemer Group Inc. now owns 123,432 shares of the biopharmaceutical company’s stock valued at $38,634,000 after buying an additional 122,811 shares during the period. 66.54% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ REGN traded down $1.40 during trading hours on Wednesday, hitting $288.31. 19,184 shares of the stock were exchanged, compared to its average volume of 647,314. The company has a quick ratio of 3.11, a current ratio of 3.88 and a debt-to-equity ratio of 0.07. The company has a market cap of $31.73 billion, a PE ratio of 14.54, a PEG ratio of 1.35 and a beta of 1.13. The firm has a fifty day moving average price of $292.02 and a 200-day moving average price of $326.19. Regeneron Pharmaceuticals Inc has a 12 month low of $271.57 and a 12 month high of $442.00.



Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.60 by $0.69. The firm had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.80 billion. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. Regeneron Pharmaceuticals’s revenue was up 20.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.45 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.22 earnings per share for the current fiscal year.

Several equities research analysts have issued reports on REGN shares. TheStreet cut shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Wednesday, June 5th. Robert W. Baird upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 price target for the company in a report on Wednesday, August 7th. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals to $344.00 and set a “market perform” rating for the company in a report on Wednesday, August 7th. Argus lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, June 18th. Finally, ValuEngine lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, June 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $396.88.

In related news, major shareholder Sanofi sold 172,904 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total transaction of $48,611,959.60. Insiders own 11.84% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: Bull Market

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.